Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
ln Vivo |
Mavodelpar (10 mg/kg; intraperitoneal injection, 10 mg/kg, once daily, 6-17 weeks of age) can effectively suppress glomerular damage and renal fibrosis, and reduce the levels of fibrosis-related proteins [1].
|
---|---|
Animal Protocol |
Animal/Disease Models: Male and female B6129SF1-Col4a3-/- mice [1]
Doses: 10 mg/kg Route of Administration: intraperitoneal (ip) injection; 10 mg/kg one time/day, 6 to 17 weeks of age Experimental Results: Inhibition of proteinuria and hematuria Burea nitrogen (BUN) level. Reduces glomerular injury, renal fibrosis, phosho-Stat3 and connective tissue growth factor (CTGF) levels. diminished expression levels of activated fibroblast marker α-SMA and collagen types I and IV. |
References |
[1]. Omachi K, et al. PPARδ agonism ameliorates renal fibrosis in an Alport syndrome mouse model. Kidney360. 2022 Nov 29.
|
Molecular Formula |
C31H29FNNAO5
|
---|---|
Molecular Weight |
537.55
|
Exact Mass |
537.560
|
Elemental Analysis |
C, 69.26; H, 5.44; F, 3.53; N, 2.61; Na, 4.28; O, 14.88
|
CAS # |
1604815-32-8
|
Related CAS # |
Mavodelpar free acid;942594-93-6
|
Appearance |
Solid powder
|
SMILES |
CC1=C(C=CC(=C1)OC/C=C(\C2=CC=C(C=C2)C#CCN3CCOCC3)/C4=CC=C(C=C4)F)OCC(=O)[O-].[Na+]
|
InChi Key |
FDJYWCAHISUZAI-MAOGHAJMSA-M
|
InChi Code |
InChI=1S/C31H30FNO5.Na/c1-23-21-28(12-13-30(23)38-22-31(34)35)37-18-14-29(26-8-10-27(32)11-9-26)25-6-4-24(5-7-25)3-2-15-33-16-19-36-20-17-33;/h4-14,21H,15-20,22H2,1H3,(H,34,35);/q;+1/p-1/b29-14+;
|
Chemical Name |
sodium;2-[4-[(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-ylprop-1-ynyl)phenyl]prop-2-enoxy]-2-methylphenoxy]acetate
|
Synonyms |
HPP-593; HPP 593; HPP593; REN 001; REN-001; REN001
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~100 mg/mL (~186.0 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8603 mL | 9.3015 mL | 18.6029 mL | |
5 mM | 0.3721 mL | 1.8603 mL | 3.7206 mL | |
10 mM | 0.1860 mL | 0.9301 mL | 1.8603 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
REN001 administration suppressed progressive proteinuria in Alport mice. Kidney360 . 2023 Mar 1;4(3):341-348. td> |
REN001 decreased the areas of tubular necrosis and fibrosis in Alport mice. Kidney360 . 2023 Mar 1;4(3):341-348. td> |
REN001 decreased expression of proteins related to inflammation and fibrosis in Alport mice. Kidney360 . 2023 Mar 1;4(3):341-348. td> |